PKKK/300/UP/018 Pengesanan Bahan Kawalan dan Terlarang dalam produk Tradisional menggunakan GCMS
- Lakukan Standard Spectra Tune (s.tune) atau Autotune (a.tune) setiap hari sebelum analisis dan pastikan laporan LULUS.
- Semak paras kebocoran udara/air (Air/Water Check): m/z 18 < 10% dan m/z 28 < 5% berbanding puncak dasar m/z 69.
- Gunakan pelarut berkualiti kromatografi gas dan pastikan septum suntikan ditukar berkala bagi mengelak 'ghost peaks'.
|
NPRA PUSAT KAWALAN KUALITI |
ARAHAN KERJA: PENGESANAN BAHAN KAWALAN DAN TERLARANG DALAM PRODUK TRADISIONAL MENGGUNAKAN GCMS | |
| No. Dokumen: PKKK/300/UP/018 | Terbitan / Semakan: Terbitan 3 Semakan 0 | |
| Tarikh Kuatkuasa: 10 April 2026 | Bahagian / Unit: SPPK · Unit Penyaringan | |
0.0 SEJARAH PINDAAN & SEMAKAN
Sejarah Pindaan & Semakan Dokumen (1 entri) ▸
Terbitan 2, Semakan 0:
PKKK/300/HMS/023 kepada PKKK/300/UAT/005
PKKK/300/HMS/031 kepada PKKK/300/UAT/011
PKKK/300/HMS/080 kepada PKKK/300/UAT/018
PKKK/300/HMS/026 kepada PKKK/300/UAT/001
PKKK/300/HMS/070 kepada PKKK/300/UAT/014
PKKK/300/HMS/071 kepada PKKK/300/UAT/015
Menambah langkah penyediaan sampel dengan lebih terperinci di para 6.4.2
Sejarah Pindaan & Semakan Dokumen (1 entri) ▸
Terbitan 2, Semakan 1:
Memansuhkan perenggan 6.2.2 dan mengemaskini ‘Preparation of working standard solution’di perenggan 6.2.1
Sejarah Pindaan & Semakan Dokumen (3 entri) ▸
Mengemaskini penomboran di perenggan 6
Menambah 6.4.2 System Suitability Test by Tuning Evaluation
Mengemaskini Appendix A
dengan menambah nota tambahan: ‘All compounds can be detected under all pH conditions and with direct dissolution in ethanol. This appendix specifies the conditions in which each compound's peak is most prominent.’
Sejarah Pindaan & Semakan Dokumen (21 entri) ▸
mengemaskini nama komponen dan penyediaan sampel pada nombor 45 dan 64.
Terbitan 2, Semakan 2:
Mengemaskini rujukan dengan menambah Buku Manual GCMS Agilent (7890/5975C), GCMS Agilent (8890/5977B) dan GCMS Shimadzu QP2010 Ultra
Mengemaskini perenggan 6.4.2 dengan menambah tuning parameter dan kriteria untuk setiap model GCMS yang digunakan
Mengemaskini perenggan 3.0 Definisi dengan menambah SPE Solid Phase Extraction, LLE Liquid Phase Extraction, LOD Limit of Detection dan PtP Peak-to-peak
Mengemaskini Appendix A dengan menambah SPE dan LLE untuk compounds yang berkenaan dan menambah compound Ticlopidine
Mengemaskini perenggan 6.3.2 kepada When samples require pH adjustment prior to analysis, either Solid-Phase Extraction (SPE) or Liquid-Liquid Extraction (LLE) may be employed
Menambah perenggan 6.4.5 Determination of LOD dan seterusnya mengemaskini kini penomboran perenggan 6.4.6 Mass Spectrum Observation dan 6.4.7 Injection Sequence.
Terbitan 2, Semakan 3:
Mengemaskini perenggan 5.4, penolong pegawai farmasi ditukar daripada U36 / U32 kepada U7 / U6.
Mengemaskini Appendix A dengan menambah compound Terbinafine
Terbitan 2, Semakan 4:
Mengemaskini perenggan 3.Definisi
Mengemaskini perenggan 6.4.2 dengan mengemaskini parameter Relative Abundance Ion m/z 219/69 dan 502/69 (Gas Chromatography Mass Spectroscopy Agilent (8890/5977B) dan (7890/5975C) dan menambahkan spesifikasi parameter untuk Atune.
Mengemaskini perenggan 6.4.2 dengan menambahkan Table 4: Tuning Parameters and Acceptance Criteria for GCMS Systems (Shimadzu).
Mengemaskini perenggan 6.4.2 dengan menambahkan kenyataan System Verification 6.4.2.4 – 6.4.2.6.
Mengemaskini perenggan 6.4.5 dengan menambah Identification of Steroids by GCMS (6.4.5.1 – 6.4.5.3)
Mengemaskini Appendix A dengan menyatakan LLE pH 7 *(Use LLE only if SPE is not feasible) untuk kompaun Betamethasone, Dexamethasone dan Prednisolone.
Mengemaskini perenggan 6.5.7 dengan menambah Tuning Report.
Mengemaskini perengan 6.4.8 dengan menggantikan nombor jadual Table 4: Injection sequence for GCMS analysis kepada Table 5: Injection sequence for GCMS analysis
Terbitan 3, Semakan 0:
Sejarah Pindaan & Semakan Dokumen (1 entri) ▸
Kemaskini tarikh kuatkuasa dari 15 Januari 2026 kepada 10 April 2026.
PKKK/300/UAT/005 kepada PKKK/300/UP/004
PKKK/300/UAT/11 kepada PKKK/300/UP/010
PKKK/300/UAT/18 kepada PKKK/300/UP/017
PKKK/300/UAT/001 kepada PKKK/300/UP/001
PKKK/300/UAT/014 kepada PKKK/300/UP/013
PKKK/300/UAT/015 kepada PKKK/300/UP/014
Sejarah Pindaan & Semakan Dokumen (1 entri) ▸
Mengemaskini perenggan 6.4.2.1 dengan menambah conduct daily tuning.
Menambah perenggan 6.4.2.4 For qualitative screening with Agilent GCMS Systems, configure the instrument using Standard Spectra Tune rather than Autotune. This preserves standard ion-ratio targets, ensuring consistent fragmentation patterns that are crucial for reliable spectral library matching.
Sejarah Pindaan & Semakan Dokumen (8 entri) ▸
Mengemaskini perenggan 6.5.6 dengan menambah utilizing the initial sample analysis as the primary basis for reporting.
Diclofenac dan ketoprofen dikeluarkan dari senarai Appendix A
Kemaskini perenggan 3 dengan menambah definisi HP 5MS, EM, m/z, PW dan NSAIDS.
Mengemaskini Relative Abundance Ion m/z 69 untuk Gas Chromatography Mass Spectrometer Shimadzu (QP2010 Ultra) di Table 4: Tuning Parameters and Acceptance Criteria for GCMS Systems (Shimadzu) kepada Ratio Precursor Ion m/z 69.
Mengemaskini para 7 Rekod Kualiti dengan menambah:
UP/001A Borang Persampelan
UP/004 Laporan Pengesanan Bahan Kawalan dan Terlarang dalam produk Tradisional
menggunakan GCMS
1.0 TUJUAN
Untuk memastikan ujian pengesanan bahan terlarang dan terhad (atau bahan kawalan dan terlarang) dalam produk tradisional menggunakan alat Gas Chromatography Mass Spectrometry (GCMS) dilaksanakan dengan cekap dan berkesan.
2.0 SKOP
6.0 PROSEDUR
Materials and Equipments
Instrument:
Gas Chromatography with single quadrupole Mass Spectrometry (EI)
Column:
HP 5MS 0.25µ, 30 m x 0.25 mm or equivalent
Reference standards:
Primary or secondary RS or equivalent (Refer Appendix A)
Chemical:
Ethanol
Glasswares and consumables:
Beakers
Volumetric Flasks (Grade A)
Nylon syringe filter 0.45 µm
Disposable syringe without needle (5 mL)
2 mL glass screw cap vial
Working standard solution
Sample handling (sampling)
Sampling processes differ between different types of dosage form. Please refer to the document PKKK/300/UP/001 (Proses Persampelan).
Sample preparation for analysis
The sample preparation process varies depending on the compound of interest. Three main methods are applied: Solid-Phase Extraction (SPE), Liquid-Liquid Extraction (LLE), and direct dissolved with ethanol.
When samples require pH adjustment prior to analysis, either Solid-Phase Extraction (SPE) or Liquid-Liquid Extraction (LLE) may be employed. Detailed procedures for both techniques can be found in documents PKKK/300/UP/013 and PKKK/300/UP/014.
For preparing samples by direct dissolving in Ethanol, the procedure is as follows:
Weight 1 gram of the sample (for dosage form such as capsule, powder, pill and cream) or measure 10 mL of the sample (for liquid dosage forms) into a beaker.
Experimental Method
The GCMS system used for detection of controlled and prohibited compounds in traditional products are given in Table 1 below.
Table 1: GCMS system for detection of controlled and prohibited compound
Column Temperature Program
Method apply column temperature program for detection of prohibited and restricted compound in traditional product:
Table 2: Column Temperature Program
Refer to document PKKK/300/UP/004 (GCMS Agilent 7890/5975C), PKKK/300/UP/010 (GCMS Shimadzu QP2010 Ultra), PKKK/300/UP/017 (GCMS Agilent 8890/5977B) on how to set-up temperature program and GCMS system.
System Suitability Test by Tuning Evaluation and System Verification
Conduct daily tuning using the system's built-in software to ensure the GCMS is performing optimally and capable of delivering accurate and reliable results.
The generated tuning report must meet predefined criteria for the GCMS model before proceeding with sample analysis.
Table 3: Tuning Parameters and Acceptance Criteria for GCMS Systems (Agilent).
Table 4: Tuning Parameters and Acceptance Criteria for GCMS Systems (Shimadzu)
For qualitative screening with Agilent GCMS Systems, configure the instrument using Standard Spectra Tune rather than Autotune. This preserves standard ion-ratio targets, ensuring consistent fragmentation patterns that are crucial for reliable spectral library matching.
For routine system performance verification, the Tune Evaluation function shall be performed daily (or as specified). This function is accessed in the instrument software by selecting Tune > Tune Evaluation.
Tune Evaluation automatically turns on the MS and collects the required data to generate a detailed verification report.
The report provides an automatic review and evaluation of key tune parameters, including: Mass Axis Calibration, Isotope Ratios, Precursor’s Presence, Air and Water Levels, and Multiplier Voltage. The acceptance criteria for evaluation remain consistent, irrespective of whether the system is evaluating a Standard Spectra Tune or an Autotune.
Standard Injection
Method verification is required when a compound of interest has not been tested (e.g. in a new instrument). Verification is performed by injecting a working standard solution once as assurance that the method is able to detect compounds with minimum library match at 80% in similarity. Repeat the process if library matching is less than minimum requirement or prepare a new working standard (by altering working standard concentration depending on peak intensity) if the problem is not resolved.
In the confirmation test (2nd analysis), a working standard solution is injected together during sample analysis (to ensure the system is at optimal condition with minimum library matching at 80%).
Sample Injection
The sample contains compounds if the retention time matched with reference standard and mass spectrum of the sample has minimum similarity matching with the library at 80%. No carry over from the previous sample is ensured by checking the chromatogram of diluent before sample injection (absent of compound detected).
Identification of Steroids by GCMS
Identification of Steroids by GCMS in Multi-Component Samples
Individual Analysis of Sample
If a received sample consists of different components or colours (e.g. a green capsule and a red capsule) and is requested for analysis using this GCMS screening method, each component shall be analysed individually. Sample extraction may utilize Solid-Phase Extraction (SPE) at varying pH levels (pH 3, 7, or 11), or by Direct Dissolve Ethanol, depending on the target analyte profile (e.g., SPE pH 3 for initial NSAID screening).
Re-analysis for Positive Screening Results
If one of the analysed sample components (e.g. the green capsule) detects the presence of a steroid compound (e.g. Dexamethasone) via the GCMS screening method, the second analyst is mandated to repeat the confirmatory analysis for that specific component. The repeat analysis must use the exact same extraction technique (e.g. SPE pH3) and test method as utilized by the first analyst.
Follow-up Action for Negative Screening Results
For any sample component that does not detect the target compound(s) via the initial GCMS screening method (e.g., the red capsule), or where the detected compound (e.g., Dexamethasone detected in SPE pH 3) is known to yield a LODcleaner, more definitive result using a different established extraction (e.g., SPE pH 7), that component shall then proceed to analysis using the specific steroid HPLC method (Method Reference: PKKK/300/UP/047), utilizing the SPE pH 7 extraction procedure.
This step is to ensure comprehensive screening, as the GCMS method may miss polar steroids or those less efficiently extracted at the initial screening pH (e.g., pH 3, optimized for NSAIDs). Switching to the HPLC method with the optimized extraction (SPE pH 7) provides the necessary sensitivity and selectivity for conclusive steroid detection.
Determination of Limit of Detection (LOD)
Limit of Detection (LOD) for a compound is determined using peak-to-peak (PtP) Signal-to-Noise Ratio (S/N) analysis.
Analyze the prepared solution to generate a PtP profile of the compound.
Calculate the Signal-to-Noise Ratio (S/N) from the PtP data.
LOD Calculation
The LOD concentration is calculated to achieve a minimum PtP S/N ratio of 3:1 using the formula:
LOD Concentration =
Example: For a 1 mg/mL (equivalent to 1000 ppm) Chlorpheniramine standard with a PtP S/N of 3924.65:
LOD Concentration =
= 0.76 ppm
Verification of LOD
If the PtP S/N ratio is less than 3, prepare a higher concentration and repeat the injection until the PtP S/N is at least 3.
This procedure provides a temporary LOD concentration for use in the confirmation test (2nd analysis) until method validation is completed.
Upon completion of method validation, the validated LOD will replace the temporary LOD and a new procedure will be developed accordingly.
Mass spectrum observation
To observe and check mass spectrum of the sample and reference standard, refer to document PKKK/300/UP/004 (GCMS Agilent 7890/5975C), PKKK/300/UP/010 (GCMS Shimadzu QP2010 Ultra), PKKK/300/UP/017 (GCMS Agilent 8890/5977B).
Injection Sequence
Injection of diluent (ethanol) must be performed before and after sample injection. Refer to Table 5 for example of sequence table:
Table 5: Injection sequence for GCMS analysis
Analysis report
Each sample will have one analysis report. Report must consist of detail as below:
Sample details (Sample name, sample number and batch number)
Analysis date
Equipment parameter including equipment name, mobile phase program, GCMS system and name of method file.
List and preparation procedures of reference standard use in analysis.
Sample preparation procedure and printed sample weight (for solid sample only)
Interpretation of result (Detected, Not Detected or suspected of specific compound),
utilizing the initial sample analysis as the primary basis for reporting.
Evidence of analysis must be attached together in analysis report:
Tuning Report
Chromatogram of 1st and 2nd injection of sample (with minimum information of compound name, peak area and retention time)
Chromatogram of 1st and 2nd injection of standard (with minimum information of compound name, peak area and retention time).
Library matching for mass spectrum of sample that have similar retention time with RS (contain information of similarity index and comparison of mass spectrum with RS)
3.0 DEFINISI
4.0 CARTA ALIRAN
Tiada carta aliran untuk prosedur ini.
5.0 TANGGUNGJAWAB
Ketua Seksyen
Memastikan prosedur ini dipatuhi semasa pengujian dijalankan
Menyemak dan mengesahkan semua laporan ujian tidak lulus yang telah disemak oleh Pegawai Farmasi termasuk laporan OOS
Ketua Unit / Pegawai Farmasi Bertanggungjawab
Memastikan prosedur ini dipatuhi semasa pengujian dijalankan
Menyemak dan mengesahkan semua laporan ujian yang telah disemak oleh Pegawai Farmasi termasuk laporan OOS
Pegawai Farmasi
Mengagihkan sampel kepada Pegawai Farmasi dan Penolong Pegawai Farmasi
Menyelia ujian yang dijalankan oleh Pegawai Farmasi dan Penolong Pegawai Farmasi
Menyemak laporan ujian
Menjalankan siasatan OOS dan menyediakan laporan OOS bagi sampel gagal ujian
Menjalankan aktiviti pengujian sampel mengikut tatacara yang telah ditetapkan
Penolong Pegawai Farmasi U7 / U6
Merekodkan bilangan ujian selepas selesai laporan ujian disiapkan untuk tujuan laporan bulanan
Menghantar laporan ujian ke Unit Perkhidmatan Analisis untuk simpanan
Menjalankan aktiviti pengujian sampel mengikut tatacara yang telah ditetapkan
7. REKOD KUALITI
No. Borang Tajuk
UP/001A Borang Persampelan
UP/004 Laporan Pengesanan Bahan Kawalan dan Terlarang dalam produk
Tradisional menggunakan GCMS
APPENDIX A
Note: All compounds can be detected under all pH conditions and with direct dissolution in ethanol. This appendix specifies the conditions in which each compound's peak is most prominent.
Jadual Kromatografi & Rujukan Data
| Terbitan | Semakan | Ditulis Oleh | Disemak Oleh | Diluluskan Oleh | Tarikh Kuatkuasa |
|---|---|---|---|---|---|
| 1 | 0 | Nur Aziah Mohd Rasali | Ooi Suat Hong | Wan Nurul Aina Mior Abdullah | 1 Nov 2022 |
| 2 | 0 | Joanne Ong Yen Nee | Ooi Suat Hong | Nur Aziah Mohd Rasali | 1 April 2024 |
| 2 | 1 | Joanne Ong Yen Nee | Ooi Suat Hong | Ida Syazrina Ibrahim | 15 Nov 2024 |
| 2 | 2 | Joanne Ong Yen Nee | Ooi Suat Hong | Ida Syazrina Ibrahim | 16 Dis 2024 |
| 2 | 3 | Tan Lu Yi | Ooi Suat Hong | Ida Syazrina Ibrahim | 1 Julai 2025 |
| 2 | 4 | Tan Lu Yi | Ooi Suat Hong | Ida Syazrina Ibrahim | 15 Jan 2026 |
| 3 | 0 | Nurul Nadiah Noh | Tan Lu Yi | Ida Syazrina Ibrahim | 10 April 2026 |
| RUJUKAN | RUJUKAN |
|---|---|
| No. Dokumen | Tajuk |
| PKKK/300/UP/004 | Gas Chromatography-Mass Spectroscopy Agilent (7890A/5975C) |
| PKKK/300/UP/010 | Gas Chromatography Mass Spectrometer Shimadzu (QP2010 Ultra) |
| PKKK/300/UP/017 | Gas Chromatography-Mass Spectroscopy Agilent (8890/5977B) |
| PKKK/300/UP/001 | Proses Persampelan (Ujian Penyaringan) |
| PKKK/300/UP/013 | Pengekstrakan Fasa Pepejal Bagi Produk Tradisional, Suplemen Kesihatan dan Kosmetik |
| PKKK/300/UP/014 | Pengekstrakan Fasa Cecair Bagi Produk Tradisional, Suplemen Kesihatan dan Kosmetik |
| Buku Manual GCMS Agilent (7890/5975C), GCMS Agilent (8890/5977B) dan GCMS Shimadzu QP2010 Ultra |
| Column | Column |
|---|---|
| Type | HP 5MS |
| Dimensions | 30 m x 0.25 mm x 0.25µm |
| Mobile phase | Mobile phase |
| Type | Helium |
| Gas flow rate | 1.0 mL/min |
| Gas Chromatography | Gas Chromatography |
| Column temperature | Temperature program |
| Injection volume | 1 µL |
| Injection mode | Splitless |
| Injector temperature (Front inlet) | 250oC |
| Run time | 32.5 minutes |
| Mass Spectrometry | Mass Spectrometry |
| Detector temperature | |
| EI / MS source | 230oC (Max 250oC) |
| Quadrupole | 150oC (Max 200oC) |
| Initial TºC | Initial Time | Max. TºC | Run time |
|---|---|---|---|
| 100oC | 2.00 min | 350oC | 32.5 |
| Ramps : | Rate | Final Temp | Final Time |
| 20.00 | 200 | 5.00 | |
| 20.00 | 260 | 5.00 | |
| 20.00 | 280 | 5.00 | |
| 20.00 | 310 | 5.00 |
| GCMS Model | Parameters | Acceptance Criteria | Acceptance Criteria |
|---|---|---|---|
| GCMS Model | Parameters | Standard Spectra Tune (s.tune) | Autotune (a.tune) |
| Gas Chromatography Mass Spectroscopy Agilent (8890/5977B) and (7890/5975C) With Tuning Standard: PFTBA (Perfluorotributylamine) | Relative Abundance Ion m/z 69 | 100% | 100% |
| Gas Chromatography Mass Spectroscopy Agilent (8890/5977B) and (7890/5975C) With Tuning Standard: PFTBA (Perfluorotributylamine) | Relative Abundance Ion m/z 219/69 | 40 - 85% | 70 – 150% |
| Gas Chromatography Mass Spectroscopy Agilent (8890/5977B) and (7890/5975C) With Tuning Standard: PFTBA (Perfluorotributylamine) | Relative Abundance Ion m/z 502/69 | 2 – 5 % | > 3% |
| Gas Chromatography Mass Spectroscopy Agilent (8890/5977B) and (7890/5975C) With Tuning Standard: PFTBA (Perfluorotributylamine) | Em Volts | ||
| Gas Chromatography Mass Spectroscopy Agilent (8890/5977B) and (7890/5975C) With Tuning Standard: PFTBA (Perfluorotributylamine) | Mass peak width (PW50) | 0.55 ± 0.1 | 0.60 ± 0.1 |
| GCMS Model | Parameters | Acceptance Criteria |
|---|---|---|
| Gas Chromatography Mass Spectrometer Shimadzu (QP2010 Ultra) | Full Width at half minimum (FWHM) | 0.5-0.7 |
| Gas Chromatography Mass Spectrometer Shimadzu (QP2010 Ultra) | Detector Voltage | |
| Gas Chromatography Mass Spectrometer Shimadzu (QP2010 Ultra) | Relative intensity ratio for m/z 502 | |
| Gas Chromatography Mass Spectrometer Shimadzu (QP2010 Ultra) | Ratio Precursor Ion m/z 69 | 100% |
| No. | Detail | No. of injection |
|---|---|---|
| 1 | Diluent (ethanol) | 1 |
| 2 | Sample number 1 | 2 |
| 3 | Diluent (ethanol) | 1 |
| 4 | Sample number 2 | 2 |
| 5 | Diluent (ethanol) | 1 |
| 6 | LOD (if any) | 1 |
| Bil | Compound name | Sample preparation |
|---|---|---|
| Alprazolam | SPE pH 3, 7, 11 and Direct dissolve ethanol | |
| Acetylsalicylic acid / aspirin | SPE pH 3 | |
| Atenolol | Direct dissolve ethanol | |
| Atropine | SPE pH 11 | |
| Benzocaine | Direct dissolve ethanol | |
| Betamethasone | i) SPE pH 7 ii) *LLE pH 7 *(Use LLE only if SPE is not feasible) | |
| Bisacodyl | Direct dissolve ethanol | |
| Bromhexine | SPE pH 11 or Direct dissolve ethanol | |
| Buclizine | SPE pH 11 or Direct dissolve ethanol | |
| Bupropion | Direct dissolve ethanol | |
| Caffeine | SPE pH 11 or Direct dissolve ethanol | |
| Camphor | Direct dissolve ethanol | |
| Captopril | Direct dissolve ethanol | |
| Carbimazole | SPE pH 12 | |
| Celecoxib | SPE pH 11 or direct dissolve ethanol | |
| Chloramphenicol | Direct dissolve ethanol | |
| Chlorpheniramine | SPE pH 11 or Direct dissolve ethanol | |
| Cinnarizine | SPE pH 11 or Direct dissolve ethanol | |
| Citalopram | SPE pH 3, 7, 11 and Direct dissolve ethanol | |
| Clindamycin | Direct dissolve ethanol | |
| Clotrimazole | SPE pH 3, 7, 11 | |
| Codeine | Direct dissolve ethanol | |
| Colchicine | SPE pH 11 or direct dissolve ethanol | |
| Cyropheptadiene | SPE pH 11 or Direct dissolve ethanol | |
| Dexamethasone | i) SPE pH 7 ii) *LLE pH 7 *(Use LLE only if SPE is not feasible) | |
| Dexchlorpheniramine | SPE pH 11 or Direct dissolve ethanol | |
| Dextromethorphan | SPE pH 11 or Direct dissolve ethanol | |
| Diazepam | SPE pH 3, 7, 11 and Direct dissolve ethanol | |
| Dibucaine | SPE pH 11 or Direct dissolve ethanol | |
| Dimenhydrinate | Direct dissolve ethanol | |
| Diphenhydramine | SPE pH 11 or Direct dissolve ethanol | |
| Diphenoxylate | SPE pH 7 | |
| Econazole | SPE pH 3, 7, 11 | |
| Ephedrine | SPE pH 11 or Direct dissolve ethanol | |
| Estradiol Benzoate | SPE pH 7 | |
| Ethinyl Oestradiol | SPE pH 7 | |
| Fenfluramine | SPE pH 5, 11 and Direct dissolve ethanol | |
| Fluoxetine | SPE pH 3, 7, 11 and Direct dissolve ethanol | |
| Griseofulvin | SPE pH 3, 7, 11 | |
| Guaifenesin | SPE pH 11 or Direct dissolve ethanol | |
| Hydroquinone | SPE pH 12 or Direct dissolve ethanol | |
| Hyoscine | SPE pH 11 | |
| Ibuprofen | SPE pH 3 | |
| Lidocaine | SPE pH 11 or Direct dissolve Ethanol | |
| Loperamide | SPE pH 11 | |
| Loratadine | SPE pH 11 or Direct dissolve ethanol | |
| Mefenamic acid | SPE pH 3 | |
| Menthol | Direct dissolve ethanol | |
| Metoclopramide | SPE pH 11 | |
| Methadone | SPE pH 11 | |
| Methamphetamine | SPE pH 3, 7, 11 and Direct dissolve ethanol | |
| Methimazole | SPE pH 12 | |
| Methyl salicylate | Direct dissolve ethanol | |
| Methyl Testosterone | SPE pH 7 | |
| Metoprolol | Direct dissolve ethanol | |
| Metronidazole | Direct dissolve ethanol | |
| Miconazole | SPE pH 3, 7, 11 | |
| Midazolam | SPE pH 3, 7, 11 and Direct dissolve ethanol | |
| Minoxidil | SPE pH 3 | |
| Morphine | SPE pH 11 | |
| N-desmethylsibutramine | SPE pH 5, 11 and direct dissolve ethanol | |
| Naproxen | SPE pH 3 | |
| Nifedipine | SPE pH 3 or Direct dissolve ethanol | |
| Nicotine | SPE pH 11 or Direct dissolve ethanol | |
| Norethisterone | SPE pH 7 | |
| Orphenadrine | SPE pH 11 | |
| Paracetamol | SPE pH 3 | |
| Phenolphthalein | Direct dissolve ethanol | |
| Phentermine | SPE pH 5, 11 and direct dissolve ethanol | |
| Phenylbutazone | SPE pH 3 | |
| Phenylpropanolamine | SPE pH 11 | |
| Prednisolone | i) SPE pH 7 ii) *LLE pH 7 *(Use LLE only if SPE is not feasible) | |
| Prilocaine | SPE pH 11 or direct dissolve Ethanol | |
| Prochlorperazine | SPE pH 11 | |
| Progesterone | SPE pH 7 | |
| Promethazine | SPE pH 11 or Direct dissolve ethanol | |
| Pseudoephedrine | SPE pH 11 or Direct dissolve ethanol | |
| Salbutamol | SPE pH 11 | |
| Salicylic acid | SPE pH 3 | |
| Sibutramine | SPE pH 5, 11 and direct dissolve ethanol | |
| Simvastatin | Direct dissolve ethanol | |
| Sulfametaxole | Direct dissolve ethanol | |
| Tadalafil | SPE pH 3 | |
| Terbinafine | SPE pH 3, 7, 11 | |
| Terbutaline | SPE pH 11 | |
| Testosterone | SPE pH 7 | |
| Testosterone Propionate | SPE pH 7 | |
| Tetracaine | SPE pH 11 or Direct dissolve ethanol | |
| Tetrahydrozoline | Direct dissolve ethanol | |
| Theophylline | SPE pH 11 | |
| Thymol | Direct dissolve ethanol | |
| Ticlopidine | SPE pH 11 | |
| Tramadol | SPE pH 11 | |
| Trimethoprim | Direct dissolve ethanol | |
| Yohimbine | Direct dissolve ethanol |